Spotlight -

Drug Development|

Quality Systems

Publication|Videos|June 6, 2024

Honeywell and the Future of Life Sciences Manufacturing

Author(s)Honeywell

Shawn Opatka, Vice President & General Manager of Life Sciences at Honeywell, discusses how the company stands out in an industry that constantly evolves.

To learn more about manufacturing in the life sciences industry, Pharmaceutical Technology sat down with Shawn Opatka, Vice President & General Manager of Life Sciences at Honeywell, at a recent INTERPHEX conference to discuss:

How automation technologies will likely evolve;
How Honeywell helps meet current industry challenges while maintaining an eye on the future;
What differentiates Honeywell from the competition in its approach to manufacturing and digitalization.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Related to this article

Regulatory Roundup—September 2026

October 2nd, 2026

Regulatory Roundup—September 2026

The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.

Novartis licenses Abogen's mRNA-encoded T-cell engager, an in vivo approach to autoimmune therapy.

October 2nd, 2026

ABO2203's $7.2B Milestones Signal RNA Capacity Demand

Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.

Drapeau’s AI Deep Dive

October 1st, 2026

Drapeau’s AI Deep Dive: The Control Lab Tested for Flavor

Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.

Ron Scarboro, Azurity Pharmaceuticals

October 1st, 2026

CPHI Milan: Medication Non-Adherence Is a Design Problem

Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.

Ronald Piervincenzi, USP

October 1st, 2026

Q&A: USP CEO Urges Manufacturers to Act Now to Stop Drug Shortages

Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.

Blur, defocused background of public exhibition hall. Business tradeshow, job fair, or stock market. Organization or company event, commercial trading, or shopping mall marketing advertisement concept | Image Credit: ©Prasit Rodphan -stock.adobe.com

September 30th, 2026

Companies Launching Equipment and Services at CPHI Milan 2026

Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.

Ronald Piervincenzi, USP

September 30th, 2026

CPHI Milan: Why One Reliable Supplier Isn't Enough

Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.

PharmTech AI Pulse Check

September 29th, 2026

PharmTech AI Pulse Check: INTerpath-001, Precision ML, Pharma's Governance Gaps

Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.

Trending on Pharmaceutical Technology

Tavapadon Sets Development Benchmark for Parkinson's

CPHI Milan 2026: Digital Supply Chains

Q&A: USP CEO Urges Manufacturers to Act Now to Stop Drug Shortages

KRAS G12D Inhibitor's $2.13B Deal Tests Cross-Border Tech Transfer

CPHI Milan: How USP Will Shape Procurement Decisions